Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2013

View Archived Issues

Abbott, Janssen and Pharmacyclics collaborate on companion test for leukemia therapy

KineMed, Isis Pharmaceuticals and CHDI Foundation form biomarker collaboration

NIH-funded trial of Shigella vaccine candidates to commence

New ACC1 inhibitors disclosed by Bayer Intellectual Property

University of Colorado and Orphan Technologies expand collaboration

FDA grants priority review to Epigenomics' PMA for Epi proColon

Zeria announces the Japanese launch of agent for hypophosphatemia

BioMarin licenses factor VIII gene therapy program for hemophilia A

Novel MPGES-1 inhibitors show promising anti-inflammatory properties

Novo Nordisk plans launch of Tresiba in Japan

Novel PAF receptor antagonists demonstrate neuroprotective properties

Abbott Laboratories synthesizes novel GlyT-1 inhibitors

Daiichi Sankyo discloses new hypoglycemic agents

Novel MAb shows potency as plasma kallikrein inhibitor

Novel RORgamma modulators patented by Tempero Pharmaceuticals

Biota Scientific Management presents new antiviral agents

Meda to begin phase II flupirtine trial in fibromyalgia

Pentraxin-related protein PTX3 levels are associated with carotid plaque vulnerability

EMA confirms decision on VIVUS' MAA for obesity treatment

Trastuzumab emtansine obtains first approval

NINDS funds tumor cell proliferation research at The Scripps Research Institute

Novartis terminates OX-17 program agreement with Orexo

NR2 peptide plasma assay as a new diagnostic tool for acute cerebrovascular events

Taxol approved for new indication in Japan

Phase III trial of cilengitide in glioblastoma fails to meet primary endpoint

Ablynx and Spirogen form anticancer drug conjugate collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...